Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder

Model scores of the 29,894 trials active now.

Model score 11% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (269 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-12-21. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: brainrandomizationdiagnosisdisordertherapy
  Phrases that lowered it: participantthe trialparticipantsconductedinvestigate
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 10.6% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Drug's FAERS reports with a death: 4.1% (lowers risk) · Drug's FDA history
• Blinding: quadruple (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: 42.5% (lowers risk) · Drug's FDA history
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 18 (lowers risk) · Sponsor's track record
• Disease area, psychiatry: Yes (raises risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 6 (lowers risk) · Who can join
• Sponsor's past trials: 113 (lowers risk) · Sponsor's track record
• Disease area, neurology: No (lowers risk) · Disease area
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder NCT05626959 · started 2022 · scored riskier than 12% of active trials completed
• Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome NCT03848832 · started 2019 · scored riskier than 17% of active trials terminated
• Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder. NCT05516407 · started 2021 · scored riskier than 10% of active trials completed
• Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures NCT04485104 · started 2021 · scored riskier than 59% of active trials terminated
• Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures NCT05288283 · started 2022 · scored riskier than 36% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.